Feb. 10 at 6:50 PM
$CLRB 🚀🚀🚀🚀
Cellectar Biosciences' Phospholipid Drug Conjugate (PDC) platform is superior due to its universal metabolic targeting of lipid rafts, which allows it to reach primary tumors, metastases, and cancer stem cells that traditional treatments often miss. Unlike Antibody-Drug Conjugates (ADCs), PDCs do not rely on specific protein antigens, making them highly resistant to the escape mechanisms tumors use to bypass conventional therapies. This small-molecule approach achieves deep intracellular delivery and exceptional tumor uptake, significantly widening the therapeutic window by reducing off-target toxicity.
💪💪💪💪
